Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
1.750
+0.030 (1.74%)
At close: Nov 25, 2025, 4:00 PM EST
1.740
-0.010 (-0.57%)
After-hours: Nov 25, 2025, 5:06 PM EST

Jasper Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
21.320.4217.0816.5711.414.8
Upgrade
Research & Development
70.2255.8251.7934.6325.4215.88
Upgrade
Operating Expenses
91.5276.2468.8651.236.8320.68
Upgrade
Operating Income
-91.52-76.24-68.86-51.2-36.83-20.68
Upgrade
Interest & Investment Income
2.345.065.20.7--
Upgrade
Other Non Operating Income (Expenses)
-0.03-0.09-0.827.09-3.08-10.99
Upgrade
EBT Excluding Unusual Items
-89.21-71.27-64.48-43.41-39.91-31.67
Upgrade
Other Unusual Items
--0.025.739.28-
Upgrade
Pretax Income
-91.02-71.27-64.47-37.69-30.64-31.67
Upgrade
Net Income
-91.02-71.27-64.47-37.69-30.64-31.67
Upgrade
Net Income to Common
-91.02-71.27-64.47-37.69-30.64-31.67
Upgrade
Shares Outstanding (Basic)
161510410
Upgrade
Shares Outstanding (Diluted)
161510410
Upgrade
Shares Change (YoY)
15.70%39.72%186.15%220.19%558.67%-
Upgrade
EPS (Basic)
-5.79-4.89-6.18-10.33-26.89-183.08
Upgrade
EPS (Diluted)
-5.79-4.89-6.18-10.33-26.89-183.08
Upgrade
Free Cash Flow
-76.53-63.15-52.33-46.43-36.11-18.27
Upgrade
Free Cash Flow Per Share
-4.87-4.33-5.01-12.73-31.69-105.60
Upgrade
EBITDA
-90.51-74.87-67.75-50.22-36.46-
Upgrade
D&A For EBITDA
1.011.371.110.980.38-
Upgrade
EBIT
-91.52-76.24-68.86-51.2-36.83-20.68
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q